Form 4: VYNE Therapeutics CEO David Domzalski Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
David Domzalski, CEO of VYNE Therapeutics, reports the disposal of shares to cover tax withholding requirements related to vesting restricted stock units.
Summary
- On March 31, 2025, David Domzalski, the President and CEO of VYNE Therapeutics Inc., disposed of shares of common stock to cover tax obligations.
- A total of 30,498 shares were disposed of at a price of $1.58 per share.
- Following the transaction, Domzalski directly owns 445,563 shares of VYNE Therapeutics Inc.
- The transaction was executed to satisfy tax withholding requirements related to the vesting of restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade in their company's stock. These filings provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of stock disposal transaction. |
| 04/02/2025 | Date of signature for the Form 4 filing. |
Keywords
VYNE Therapeutics, David Domzalski, Form 4, Stock Disposal, Tax Withholding, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.